Rose G. McHardy
Research Subjects
Rose G. McHardy has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Sala
University of Strathclyde, Glasgow, United Kingdom
7 shared publications - David S. Palmer
Department of Pure and Applied Chemistry, University of Strathclyde, Thomas Graham Building, 295 Cathedral Street, Glasgow G1 1XL, U.K.
7 shared publications - Edward Parkin
National Health Service Foundation Trust 3 Department of Colorectal Surgery, Lancashire Teaching Hospitals Royal Preston Hospital, Preston, United Kingdom
7 shared publications - Holly J. Butler
Dxcover Ltd., Glasgow, United Kingdom
7 shared publications - James M. Cameron
WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde, Technology and Innovation Centre, 99 George Street, Glasgow, G1 1RD, UK
7 shared publications - Matthew J. Baker
Dxcover Ltd, Royal College Building, Suite RC534, Glasgow, UK; School of Medicine & Dentistry, University of Lancashire, Preston, UK
7 shared publications
Latest Publications
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Supplementary Table S1. Histopathology classification used to assign class labels for the machine learning models.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Supplementary Table S1. Histopathology classification used to assign class labels for the machine learning models.
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Supplementary Table S2. Additional statistics from an alternative machine learning approach, described in the Methods. Models have been tuned to 90% specificity for the cross-validation.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Supplementary Table S2. Additional statistics from an alternative machine learning approach, described in the Methods. Models have been tuned to 90% specificity for the cross-validation.
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Data from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes and limiting disease progression. Screening of average-risk individuals is essential for detecting tumors at an earlier, more treatable stage. However, adherence to current screening programs remains suboptimal. Liquid biopsies represent a promising alternative to stool-based tests and may play a key role in optimizing colorectal cancer detection and diagnostic pathways. In this study, 957 patients were recruited across various clinical sites in the United States: 48 with colorectal cancer, 157 with advanced precancerous lesions (APL), 331 with nonadvanced lesions, and 421 with a negative colonoscopy diagnosis. Blood was obtained from patients either prior to scheduled colonoscopy or before surgical resection and any anticancer therapies. Streck plasma samples were analyzed by the Dxcover Liquid Biopsy Platform and classified using machine learning algorithms. When colorectal cancer was classified against all other groups, the ROC curve generated an AUC value of 0.95, and test sensitivity and specificity were 90% and 89%, respectively. The diagnostic model accurately predicted 75% of stage I (3/4), 100% of stage II (15/15), 93% of stage III (14/15), and 100% of stage IV (6/6) colorectal cancers. For the advanced colorectal neoplasia model, 29% of APL were detected. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer.Prevention Relevance:Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes and limiting disease progression. Screening of average-risk individuals is essential for detecting tumors at an earlier, more treatable stage. However, adherence to current screening programs remains suboptimal. Liquid biopsies represent a promising alternative to stool-based tests and may play a key role in optimizing colorectal cancer detection and diagnostic pathways. In this study, 957 patients were recruited across various clinical sites in the United States: 48 with colorectal cancer, 157 with advanced precancerous lesions (APL), 331 with nonadvanced lesions, and 421 with a negative colonoscopy diagnosis. Blood was obtained from patients either prior to scheduled colonoscopy or before surgical resection and any anticancer therapies. Streck plasma samples were analyzed by the Dxcover Liquid Biopsy Platform and classified using machine learning algorithms. When colorectal cancer was classified against all other groups, the ROC curve generated an AUC value of 0.95, and test sensitivity and specificity were 90% and 89%, respectively. The diagnostic model accurately predicted 75% of stage I (3/4), 100% of stage II (15/15), 93% of stage III (14/15), and 100% of stage IV (6/6) colorectal cancers. For the advanced colorectal neoplasia model, 29% of APL were detected. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer.Prevention Relevance:Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer.
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Supplementary Figure S2. The mean receiver operating characteristic curve for the advanced colorectal neoplasia model, showing the trade-off between sensitivity (Sens) and specificity (Spec). AUC denotes the area under the curve.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Supplementary Figure S2. The mean receiver operating characteristic curve for the advanced colorectal neoplasia model, showing the trade-off between sensitivity (Sens) and specificity (Spec). AUC denotes the area under the curve.
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Supplementary Figure S3. Relationship between specificity and APL sensitivity for the advanced colorectal neoplasia model.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Supplementary Figure S3. Relationship between specificity and APL sensitivity for the advanced colorectal neoplasia model.
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Supplementary Figure S1. Flow diagram illustrating the data analysis process, detailing the cross-validation approach used to report model performance.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Supplementary Figure S1. Flow diagram illustrating the data analysis process, detailing the cross-validation approach used to report model performance.
- Open Access
- 23 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (3) , 145-152
A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes and limiting disease progression. Screening of average-risk individuals is essential for detecting tumors at an earlier, more treatable stage. However, adherence to current screening programs remains suboptimal. Liquid biopsies represent a promising alternative to stool-based tests and may play a key role in optimizing colorectal cancer detection and diagnostic pathways. In this study, 957 patients were recruited across various clinical sites in the United States: 48 with colorectal cancer, 157 with advanced precancerous lesions (APL), 331 with nonadvanced lesions, and 421 with a negative colonoscopy diagnosis. Blood was obtained from patients either prior to scheduled colonoscopy or before surgical resection and any anticancer therapies. Streck plasma samples were analyzed by the Dxcover Liquid Biopsy Platform and classified using machine learning algorithms. When colorectal cancer was classified against all other groups, the ROC curve generated an AUC value of 0.95, and test sensitivity and specificity were 90% and 89%, respectively. The diagnostic model accurately predicted 75% of stage I (3/4), 100% of stage II (15/15), 93% of stage III (14/15), and 100% of stage IV (6/6) colorectal cancers. For the advanced colorectal neoplasia model, 29% of APL were detected. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer. Prevention Relevance: Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer.
- 23 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (3) , 145-152
Open AccessA Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer
Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes and limiting disease progression. Screening of average-risk individuals is essential for detecting tumors at an earlier, more treatable stage. However, adherence to current screening programs remains suboptimal. Liquid biopsies represent a promising alternative to stool-based tests and may play a key role in optimizing colorectal cancer detection and diagnostic pathways. In this study, 957 patients were recruited across various clinical sites in the United States: 48 with colorectal cancer, 157 with advanced precancerous lesions (APL), 331 with nonadvanced lesions, and 421 with a negative colonoscopy diagnosis. Blood was obtained from patients either prior to scheduled colonoscopy or before surgical resection and any anticancer therapies. Streck plasma samples were analyzed by the Dxcover Liquid Biopsy Platform and classified using machine learning algorithms. When colorectal cancer was classified against all other groups, the ROC curve generated an AUC value of 0.95, and test sensitivity and specificity were 90% and 89%, respectively. The diagnostic model accurately predicted 75% of stage I (3/4), 100% of stage II (15/15), 93% of stage III (14/15), and 100% of stage IV (6/6) colorectal cancers. For the advanced colorectal neoplasia model, 29% of APL were detected. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer. Prevention Relevance: Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer.